Live Ready-to-Use Models Now Available – No Wait Times!

GenoBioTX is pleased to announce the availability of ready-to-use knockout (KO), knock-in (KI), and overexpression models for preclinical research. With no wait times, researchers can now accelerate their studies using our live genetically engineered models, ensuring efficiency and reliability in critical research areas.

Advancing Preclinical Research Across Key Areas

Our live models are designed to support a wide range of disease applications, including:

Oncology

  • Knockout and knock-in models for tumor research and targeted therapy development

Neurology

  • Overexpression models for neurodegenerative diseases and CNS disorders

Metabolic & Cardiovascular Research

  • KO/KI models for diabetes, obesity, and atherosclerosis

Autoimmune & Infectious Diseases

  • Genetically modified mice for immune system and pathogen response studies

Immediate Availability for Researchers

By eliminating long lead times, these models allow researchers to rapidly initiate their studies without delays, expediting advancements in drug discovery and therapeutic development.

📄 Explore our full list of available live animal models to find the best fit for your research needs.

📩 Contact us today to discuss your project and secure immediate access to these models.

    News Center

    2024.11.01

    Why IL-2 Still Holds Promise in Therapeutics of Cancer and Autoimmunity

    Aclidineleukin (high-dose IL-2) is the first FDA-approved cancer immunotherapy for metastatic renal cell carcinoma (RCC) and melanoma, but the widespread clinical use of aclidinein has been limited by its short half-life, serious side effects, and simultaneous stimulation of Treg activation. With the breakthrough of studies of immune checkpoint inhibitors, IL-2-based therapeutics has regained widespread attention, […]

    2025.04.07

    Connect with GenoBioTX at AACR 2025

    We look forward to connecting with you at the upcoming AACR Annual Meeting in Chicago from April 25–30! At GenoBioTX, we understand that robust, translationally relevant preclinical models are critical for confident decision-making in oncology drug development. We specialize in developing genetically modified and humanized mouse models that provide the insights necessary to effectively evaluate […]

    Email Back to top